AUTHOR=Korten Insa , Kieninger Elisabeth , Krueger Linn , Bullo Marina , Flück Christa E. , Latzin Philipp , Casaulta Carmen , Boettcher Claudia 

TITLE=Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study

JOURNAL=Frontiers in Pediatrics

VOLUME=10

YEAR=2022

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.852551

DOI=10.3389/fped.2022.852551

ISSN=2296-2360

ABSTRACT=<sec><title>Background</title><p>The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance.</p></sec><sec><title>Methods</title><p>Sixteen adolescents with CF performed oral glucose tolerance tests (OGTT) before and 4–6 weeks after initiating ELX/TEZ/IVA therapy. A continuous glucose monitoring (CGM) system was used 3 days before until 7 days after starting ELX/TEZ/IVA treatment.</p></sec><sec><title>Results</title><p>OGTT categories improved after initiating ELX/TEZ/IVA therapy (<italic>p</italic> = 0.02). Glucose levels of OGTT improved at 60, 90, and 120 min (<italic>p</italic> &lt; 0.05), whereas fasting glucose and CGM measures did not change.</p></sec><sec><title>Conclusion</title><p>Shortly after initiating ELX/TEZ/IVA therapy, glucose tolerance measured by OGTT improved in people with CF. This pilot study indicates that ELX/TEZ/IVA treatment has beneficial effects on the endocrine pancreatic function and might prevent or at least postpone future CFRD.</p></sec>